Scott Whitcup Net Worth

Scott Whitcup biography

Dr. Scott Whitcup M.D. serves as Independent Director of the Company. He has also served on the clinical faculty at the UCLA Stein Eye Institute since July 2003. Previously, Dr. Whitcup served in a number of positions at Allergan, Inc., most recently as the executive vice president of research and development and chief scientific officer, from April 2009 to March 2015. Earlier in his career, Dr. Whitcup was the clinical director at the National Eye Institute at the National Institutes of Health. He previously served on the boards of Menlo Therapeutics Inc., a biopharmaceutical company, and Nightstar Therapeutics plc, a gene therapy company and currently serves on a number of private company boards. Dr. Whitcup earned a B.A. from Cornell University and an M.D. from Cornell University Medical College. He completed an internal medicine residency at UCLA and an ophthalmology residency at Harvard University at the Massachusetts Eye and Ear Infirmary. Dr. Whitcup has been chosen to serve on our Board due to his extensive experience in the discovery, development, and commercialization of drug products, his ophthalmologic expertise and his experience serving as a director for public companies.

How old is Scott Whitcup?

Scott Whitcup is 60, he's been the Independent Director of Adverum Biotechnologies Inc since 2020. There are 5 older and 13 younger executives at Adverum Biotechnologies Inc. The oldest executive at Adverum Biotechnologies Inc is Richard Spivey, 69, who is the Independent Director.

What's Scott Whitcup's mailing address?

Scott's mailing address filed with the SEC is C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY, CA, 94063.

Insiders trading at Adverum Biotechnologies Inc

Over the last 9 years, insiders at Adverum Biotechnologies Inc have traded over $1,591,374 worth of Adverum Biotechnologies Inc stock and bought 912,973 units worth $4,153,055 . The most active insiders traders include Patrick Machado, Braden Michael Leonard oraz Thomas Woiwode. On average, Adverum Biotechnologies Inc executives and independent directors trade stock every 40 days with the average trade being worth of $200,186. The most recent stock trade was executed by Braden Michael Leonard on 30 July 2024, trading 85,800 units of ADVM stock currently worth $613,470.

What does Adverum Biotechnologies Inc do?

adverum (nasdaq: advm) is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. we are advancing the development of a robust pipeline of gene therapies that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (a1at) deficiency and hereditary angioedema (hae) as well as wet age-related macular degeneration (wamd). leveraging our next-generation adeno-associated virus (aav)-based directed evolution platform, we generate gene therapies designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.

Adverum Biotechnologies Inc executives and stock owners

Adverum Biotechnologies Inc executives and other stock owners filed with the SEC include:

• Leone Patterson,
  President
• Thomas Leung,
  Chief Financial Officer
• Aaron Osborne,
  Chief Medical Officer
• Dr. Laurent Fischer,
  Pres, CEO, Interim CMO & Director
• Dr. Brigit Riley Ph.D.,
  Chief Scientific Officer
• Rekha Hemrajani,
  Independent Director
• James Scopa,
  Independent Director
• Mark Lupher,
  Independent Director
• Patrick Machado,
  Independent Chairman of the Board
• Richard Spivey,
  Independent Director
• Eric Carter,
  Independent Director
• Thomas Woiwode,
  Independent Director
• Mehdi Gasmi,
  Director
• Myesha Lacy,
  Vice President, Investor Relations and Corporate Communications
• Scott Whitcup,
  Independent Director
• Peter Soparkar,
  Chief legal officer
• Christopher Morrison,
  Vice President - Process Development
• Thomas Kochy,
  Vice President - Commercial and Program Strategy
• Heikki Jouttijarvi,
  Vice President - Manufacturing
• Angela Thedinga,
  Chief Technology Officer
• Laurent Fischer,
  Chief Executive Officer, Director
• Carla Fiankan,
  Sr. VP of Regulatory Affairs
• Nancy E. Pecota,
  Principal Accounting Officer
• John W. Rakow J.D.,
  Sr. VP, Gen. Counsel & Acting CFO
• Anand Reddi,
  VP, Head of Corp. Strategy & External Affairs and Engagement
• Michael Steel,
  Sr. VP of Quality
• Dr. Jim Wang Ph.D.,
  Sr. VP & Head of Regulatory Affairs
• Dena House,
  Sr. VP of HR, Organizational Devel. & Learning
• Kishor Peter Soparkar J.D.,
  Chief Operating Officer
• Dr. Rupert D'Souza M.B.A., Ph.D.,
  Chief Financial Officer
• Steven Daniel Schwartz,
  Director
• Samuel B. Barone,
  SVP, Clinical Development
• Athena Countouriotis,
  SVP, Chief Medical Officer
• Mitchell H. Finer,
  Director
• Carlo Russo,
  EVP and Chief Medical Officer
• Jennifer C. Cheng,
  General Counsel
• Amber Salzman,
  President and CEO
• Paul B Cleveland,
  Chief Executive Officer
• Richard Beckman,
  Chief Medical Officer
• Szilard Kiss,
  
• Soo Hong,
  
• Rabia Gurses Ozden,
  Chief Medical Officer
• Linda M Rubinstein,
  CHIEF FINANCIAL OFFICER
• Dawn Svoronos,
  
• Reed Vaughn Tuckson,
  
• Rupert D'souza,
  Chief Financial Officer
• Julie Clark,
  Chief Medical Officer
• Setareh Seyedkazemi,
  CHIEF DEVELOPMENT OFFICER
• Braden Michael Leonard,
  
• Brigit Riley,
  Chief Scientific Officer
• John Rakow,
  SVP, Genl Counsel, Acting CFO
• C. David Nicholson,,